Jupiter Neurosciences adds health economist Tomas Philipson to board

Jupiter Neurosciences, Inc. disclosed in an 8-K dated June 26, 2026 that its Board of Directors appointed Tomas J. Philipson, Ph.D. to serve as a member of the Board, effective immediately.¹ Dr. Philipson will serve until the next annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation, or removal.¹

In connection with his appointment, Dr. Philipson was also appointed to serve as a member of the Audit Committee and the Compensation Committee of the Board, in each case effective on the same date as his appointment to the Board.¹

According to the filing, Dr. Philipson, age 64, is a health care economist with experience across academia, government, and the private sector, and since June 2020 has been self-employed through his consulting firm, TJP Economic Consulting Inc., where he advises senior executives at biopharmaceutical and health care companies on economic and policy matters.¹ The filing also lists that he currently serves as Managing Partner of MEDA Ventures since 2023¹ and has held roles including Acting Chairman of the White House Council of Economic Advisers from June 2019 to June 2020 and as a member of the Council of Economic Advisers from 2017 to 2020.¹

For his board service, Dr. Philipson will receive equity compensation in lieu of participating in the Company's standard cash compensation program for non-employee directors: a sign-on option to purchase 90,000 shares of the Company's common stock at an exercise price equal to the fair market value on June 29, 2026, vesting in equal quarterly installments over 36 months, subject to continued service as a director; and, in lieu of cash compensation otherwise payable as an annual cash retainer and committee fees, an option to purchase 446,428 shares of the Company's common stock at an exercise price equal to the fair market value on the Grant Date, vesting in equal quarterly installments over 36 months, subject to continued service as a director.¹

The filing states there are no arrangements or understandings between Dr. Philipson and any other persons pursuant to which he was selected as a director, and there are no transactions involving Dr. Philipson requiring disclosure under Item 404(a) of Regulation S-K.¹ The report was signed by Chief Executive Officer Christer Rosén on June 30, 2026.